Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 2/20 | 0.44 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | TBXA2R | P21731 | 5/20 | 0.32 |
| ▸ | PTGIR | P43119 | 5/20 | 0.32 |
| ▸ | PRNP | P04156 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | PSMB5 | P28074 | 6/20 | 0.31 |
| ▸ | PSMB8 | P28062 | 3/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9843997 | 0.85 | LOXL2 (0.35) | MAOBLOXL2 | |
| SCHEMBL21455346 | 0.83 | LOXL2 (0.44) | MAOBLOXL2 | |
| SCHEMBL6299352 | 0.83 | GABRA1 (0.47) | MAOBLOXL2SMN1; SMN2TBXA2RPTGIR | |
| SCHEMBL31534803 | 0.79 | LOXL2 (0.32) | MAOBLOXL2TBXA2RPTGIR | |
| SCHEMBL13298379 | 0.79 | CYP17A1 (0.40) | MAOBPSMB5PSMB8 | |
| SCHEMBL23218984 | 0.77 | MAOB (0.37) | MAOBKDM4E | |
| SCHEMBL17652414 | 0.77 | PSMB5 (0.46) | MAOBSMN1; SMN2PSMB5PSMB8 | |
| SCHEMBL20765804 | 0.77 | PSMB5 (0.46) | MAOBSMN1; SMN2KDM4EPSMB5PSMB8 | |
| SCHEMBL17653768 | 0.76 | MAOB (0.43) | MAOBSMN1; SMN2TBXA2RPTGIRPSMB5 | |
| SCHEMBL5544888 | 0.75 | LOXL2 (0.33) | MAOBLOXL2TBXA2RPTGIR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12558341-B2 | Oral complement factor D inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| US-20250186391-A1 | ORAL COMPLEMENT FACTOR D INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2025-06-12 | — | — | US | disclosed |
| WO-2025055856-A1 | P53-Y220C-SELECTIVE SMALL-MOLECULE REACTIVATOR COMPOUND, PHARMACEUTICAL COMPOSITION, AND USE THEREOF | 长春金赛药业有限责任公司 | 2025-03-20 | — | — | WO | disclosed |
| CN-118852259-A | P53-Y220C selective small molecule reactivation agent compound, pharmaceutical composition and application thereof | 长春金赛药业有限责任公司 | 2024-10-29 | — | — | CN | disclosed |
| WO-2024215802-A1 | BENZOFURANYL AND BENZOTHIENYL COMPOUNDS AS P53 MODULATORS | NESTED THERAPEUTICS, INC. (US) | 2024-10-17 | — | — | WO | disclosed |
| CN-117986235-A | P53-Y220C selective small molecule reactivation agent compound, pharmaceutical composition and application thereof | 长春金赛药业有限责任公司 | 2024-05-07 | — | — | CN | disclosed |
| EP-4041238-A1 | ORAL COMPLEMENT FACTOR D INHIBITORS | Biocryst Pharmaceuticals, Inc. (US) | 2022-08-17 | — | — | EP | disclosed |
| CN-114502168-A | Oral complement factor D inhibitors | 拜奥克里斯特制药公司 | 2022-05-13 | — | — | CN | disclosed |
| WO-2021072198-A1 | ORAL COMPLEMENT FACTOR D INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2021-04-15 | — | — | WO | disclosed |
| WO-2021072198-A1 | ORAL COMPLEMENT FACTOR D INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2021-04-15 | — | — | WO | disclosed |
| EP-0445073-A1 | Benzofurans | CIBA-GEIGY AG (CH) | 1991-09-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12558341-B2 | Oral complement factor D inhibitors | CFD, CFH, CFB | MAOB 1035/4885LOXL2 1245/4885SMN1; SMN2 3739/4885 |
| US-20250186391-A1 | ORAL COMPLEMENT FACTOR D INHIBITORS | CFD, CFH, CFB | MAOB 453/4885LOXL2 2434/4885SMN1; SMN2 3669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.